CLChun-Che Lin

Chun-Che Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chun-Che Lin has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PNU-74654 Induces Cell Cycle Arrest and Inhibits EMT Progression in Pancreatic Cancer

    by Tai-Long Chien, Yao-Cheng Wu, Hsiang-Lin Lee, Wen-Wei Sung, Chia-Ying Yu, Ya-Chuan Chang, Chun-Che Lin, Chi-Chih Wang, Ming-Chang Tsai

    Background and Objectives: PNU-74654, a Wnt/β-catenin pathway inhibitor, has an antiproliferative effect on many cancer types; however, its therapeutic role in pancreatic cancer (PC) has not yet been demonstrated. Here, the effects of PNU-74654 on proliferation and cell cycle phase distribution were studied in PC cell lines. Materials and Methods: The cancer-related molecular pathways regulated by PNU-74654 were determined by a proteome profiling oncology array and confirmed by western blotting. Results: The cell viability and proliferative ability of PC cells were decreased by PNU-74654 treatment. G1 arrest was observed, as indicated by the downregulation of cyclin E and cyclin-dependent kinase 2 (CDK2) and the upregulation of p27. PNU-74654 inhibited the epithelial–mesenchymal transition (EMT), as determined by an increase in E-cadherin and decreases in N-cadherin, ZEB1, and hypoxia-inducible factor-1 alpha (HIF-1α). PNU-74654 also suppressed cytoplasmic and nuclear β-catenin and impaired the NF-κB pathway. Conclusions: These results demonstrate that PNU-74654 modulates G1/S regulatory proteins and inhibits the EMT, thereby suppressing PC cell proliferation, migration, and invasion. The synergistic effect of PNU-74654 and chemotherapy or the exclusive use of PNU-74654 may be therapeutic options for PC and require further investigation.


  • Open Access

    Favorable gallbladder cancer mortality-to-incidence ratios of countries with good ranking of world’s health system and high expenditures on health

    by Chi-Chih Wang, Ming-Chang Tsai, Shao-Chuan Wang, Cheng-Ming Peng, Hsiang-Lin Lee, Hsuan-Yi Chen, Tzu-Wei Yang, Chun-Che Lin, Wen-Wei Sung

    The mortality-to-incidence ratio (MIR) is a marker that reflects the clinical outcome of cancer treatment. MIR as a prognostic marker is more accessible when compared with long-term follow-up survival surveys. Theoretically, countries with good health care systems would have favorable outcomes for cancer; however, no report has yet demonstrated an association between gallbladder cancer MIR and the World’s Health System ranking. We used linear regression to analyze the correlation of MIRs with the World Health Organization (WHO) rankings and total expenditures on health/gross domestic product (e/GDP) in 57 countries selected according to the data quality. The results showed high crude rates of incidence/mortality but low MIR in more developed regions. Among continents, Europe had the highest crude rates of incidence/mortality, whereas the highest age-standardized rates (ASR) of incidence/mortality were in Asia. The MIR was lowest in North America and highest in Africa (0.40 and 1.00, respectively). Furthermore, favorable MIRs were correlated with good WHO rankings and high e/GDP (p = 0.01 and p = 0.030, respectively). The MIR variation for gallbladder cancer is therefore associated with the ranking of the health system and the expenditure on health.


  • Open Access

    Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study

    by Chi-Chih Wang, Ming-Chang Tsai, Wen-Wei Sung, Tzu-Wei Yang, Hsuan-Yi Chen, Yao-Tung Wang, Chang-Cheng Su, Ming-Hseng Tseng, Chun-Che Lin

    Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study


  • High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy

    by Tsung-Ming Chen, Chun-Che Lin, Pi-Teh Huang, Chen-Fan Wen

    Salient studies have investigated the association between host inflammatory response and cancer. This study was conducted to test the hypothesis that peripheral absolute monocyte counts (AMC) could impart an increased risk of hepatocellular carcinoma (HCC) development in hepatitis C virus (HCV)-infected patients after a failed peginterferon/ribavirin (PR) combination therapy. A total of 723 chronic HCV-infected patients were treated with PR, of which 183 (25.3 %) patients did not achieve a sustained virological response (non-SVR). Post-treatment AMC values were measured at 6 months after end of PR treatment. Fifteen (2.8 %) of 540 patients with an SVR developed HCC during a median follow-up period of 41.4 months, and 14 (7.7 %) of 183 non-SVR patients developed HCC during a median follow-up of 36.8 months (log rank test for SVR vs. non-SVR, P = 0.002). Cox regression analysis revealed that post-treatment AFP level (HR 1.070; 95 % CI = 1.024–1.119, P = 0.003) and post-treatment aspartate aminotransferase (AST)-to-platelet ratio index (APRI) ≥0.5 (HR 4.401; 95 % CI = 1.463–13.233, P = 0.008) were independent variables associated with HCC development for SVR patients. For non-SVR patients, diabetes (HR 5.750; 95 % CI = 1.387–23.841, P = 0.016), post treatment AMC ≥370 mm−3 (HR 5.805; 95 % CI = 1.268–26.573, P = 0.023), and post-treatment APRI ≥1.5 (HR 10.905; 95 % CI = 2.493–47.697, P = 0.002) were independent risks associated with HCC. In conclusion, post-treatment AMC has a role in prognostication of HCC development in HCV-infected patients who failed to achieve an SVR after PR combination therapy.


  • Open Access

    Performance of Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH‐B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients

    by T.‐M. Chen, C.‐C. Chang, P.‐T. Huang, C.‐F. Wen, C.‐C. Lin

    Summary: Background: REACH‐B [Risk Estimation for Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B] scoring system was developed to predict the risk of HCC in noncirrhotic chronic hepatitis B (CHB) patients.Aim: To evaluate the discriminatory performance of REACH‐B scoring system in classifying anti‐viral treatment eligibility of CHB patients according to the 2012 Asian Pacific Association for the Study of the Liver (APASL) treatment guideline.Methods: A total of 904 noncirrhotic CHB were enrolled. Patients' age, gender, liver biochemistry, HBeAg status and HBV DNA levels were recorded.Results: The minimum REACH‐B risk score for patients to be eligible for anti‐viral treatment was 7 for HBeAg‐positive and 6 for HBeAg‐negative patients. Among them, increasing REACH‐B score was not significantly associated with eligibility for treatment [adjusted odds ratio (OR): 1.210, 95% confidence interval (CI): 0.979–1.494, P = 0.078] in HBeAg‐positive patients, as shown by logistic regression analysis after adjusting for gender. In HBeAg‐negative patients, REACH‐B score significantly predicted the treatment eligibility (adjusted OR: 1.783, 95% CI: 1.607–1.979, P < 0.001). Discriminatory ability of REACH‐B score to classify eligibility was poor for HBeAg‐positive patients ≥40 years [area under receiver operating characteristic (AUC): 0.664, 95% CI: 0.533–0.795], but good/excellent for HBeAg‐positive patients <40 years (AUC: 0.903; 95% CI: 0.841–0.964), HBeAg‐negative patients ≥45 years (AUC: 0.883; 95% CI: 0.848–0.917) and HBeAg‐negative patients <45 years (AUC: 0.907; 95% CI: 0.874–0.940).Conclusion: The discriminatory performance of the REACH‐B scoring system in classifying anti‐viral treatment eligibility based on the 2012 APASL guideline was good/excellent, except for ≥40 years old HBeAg‐positive patients.


  • Neutrophil‐to‐lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation

    by Tsung‐Ming Chen, Chun‐Che Lin, Pi‐Teh Huang, Chen‐Fan Wen

    Background and Aim:  Increasing evidence correlates the presence of systemic inflammation with poor survival in patients with hepatocellular carcinoma (HCC). We studied whether peripheral blood neutrophil‐to‐lymphocyte ratio (NLR), a marker of systemic inflammatory response, would be a useful predictor for outcome in patients with early HCC undergoing radiofrequency ablation (RFA).Methods:  A total of 158 patients with early HCC underwent RFA. Potential prognostic factors such as age, gender, tumoral characteristics, Child‐Turcotte‐Pugh (CTP) class and NLR were analyzed. The study endpoints were overall survival (OS) and new recurrence.Results:  We modeled NLR as a continuous explanatory variable in regression analyses. Multivariate analysis revealed that tumor size (P = 0.005) and high baseline NLR (P = 0.001) were independent explanatory variables associated with unfavorable OS. Regarding new recurrence, multivariate analysis showed that CTP class B (P = 0.002), α‐fetoprotein > 400 ng/mL (P = 0.030), tumor size (P = 0.002) and tumor multiplicity (P = 0.013) were found to be worse prognosticators, but not baseline NLR. In a subset analysis of 140 patients whose post‐RFA NLR data at first follow‐up visit were available, multivariate analysis revealed that high post‐RFA NLR was identified as an independent covariate, not only for OS (P = 0.006), but for new recurrence (P = 0.010) as well.Conclusions:  High baseline NLR was associated with worse OS for patients with early HCC; post‐RFA NLR predicted not only OS, but also tumor recurrence.


  • Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation

    by Tsung‐Ming Chen, Chun‐Che Lin, Pi‐Teh Huang, Chen‐Fan Wen

    Background and Aim:  Type 2 diabetes increases the risk of cancer development and mortality. However, antidiabetic treatment with metformin can reduce the risk of cancer. We studied whether metformin users among diabetic patients with early hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) would have a favorable survival compared with those without metformin treatment.Methods:  A total of 135 patients with early stage HCC having 162 tumors underwent RFA. Among them, 53 patients were diabetic, including 21 metformin users and 32 patients without metformin treatment.Results:  Diabetic patients had an inferior survival rate compared with nondiabetic patients (1 year, 82.8% vs 93.9%; 3 years, 55.1% vs 80.2%; 5 years, 41.3% vs 64.7%; P = 0.004). With regards to antidiabetic treatments, metformin users had better survival outcome (adjusted hazard ratio [HR] 0.24; 95% confidence interval [CI], 0.07–0.80; P = 0.020) compared to patients without metformin treatment after adjustments for potential confounders. Sulfonylureas and insulin exposures did not achieve significant conclusions. For the whole studied population including nondiabetic and diabetic patients, the multivariate analysis revealed that maximum tumor size more than 2.5 cm (HR, 3.49; 95% CI, 1.74–6.99; P < 0.001) and diabetic patients without metformin treatment (HR, 3.34; 95% CI, 1.67–6.71, P = 0.001) were independent explanatory variables associated with unfavorable survival.Conclusions:  Metformin users among diabetic patients with HCC undergoing RFA had a favorable overall survival compared with patients without metformin treatment.